Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis

flares in adults in major markets including the US, Japan, Mainland China and the EU,” said Carinne Brouillon, member of the board of managing directors, responsible for human pharma at BI.

Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP

The therapy is already approved in major markets, including in the US for moderate-to-severe plaque psoriasis, as well as in Japan for plaque psoriasis, generalised pustular psoriasis and erythrodermic

Pfizer and Gero collaborate on fibrotic disease research

and holds commercial rights in the US and Japan. ... Pfizer will hold a 25% stake in the new business and will maintain commercial rights outside the US and Japan.

Biogen and Eisai’s Alzheimer’s drug receives FDA accelerated approval

We will continue to actively cooperate with the FDA's review.”. The Japanese company said it also planned to apply for marketing authorisation for Leqembi in Japan and the EU by

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]